Hemophilia B

Chapel Hill Strain of Hemophilia B Dogs Ideal Gene Therapy Model

Published in Blood Weekly, October 5th, 2000

Because hemophilia B dogs from the University of North Carolina-Chapel Hill colony do not have any circulating Factor IX antigen in plasma, they are ideal candidates for testing the effectiveness of gene therapy protocols, researchers say.

"The molecular and biochemical characterization of the Chapel Hill strain of hemophilia B dogs includes precise conditions required for immunodetection of trace amounts of canine factor IX (cFIX)," stated Timothy C. Nichols and colleagues from the UNC-CH, the University of Pennsylvania, and the Children's Hospital of Philadelphia, Pennsylvania.

"The causative genetic defect is a missense mutation (G to A at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-10-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry